摘要
目的探讨血清人类可溶性程序性死亡配体-1(sPD-L1)和血管内皮细胞生长因子(VEGF)对食管鳞癌(ESCC)患者预后的评估价值。方法选取经术后病理确诊为ESCC的患者105例,以35例健康体检者作为对照。检测血清sPD-L1、VEGF水平并比较其水平的差异,分析其与患者生存时间的关系。结果ESCC组血清sPD-L1、VEGF的水平与正常对照组比较,差异均有统计学意义(P<0.05)。有家族史的患者的血清VEGF的水平高于没有家族史的患者(P<0.05);血清sPD-L1、VEGF的水平在有无淋巴结转移的分组比较中差异有统计学意义(P<0.05)。生存时间<3年的患者的血清sPD-L1、VEGF水平高于生存时间>3年的患者(P<0.05)。受试者工作特征(ROC)曲线结果显示,血清sPD-L1、VEGF预测ESCC患者3年内死亡的AUC分别为0.820、0.733,两者联合预测3年内死亡的AUC为0.842。其敏感性为84.7%,特异性为78.3%。结论血清sPD-L1、VEGF可以作为食管鳞癌预后判断的参考依据。
【Objective】To investigate the prognostic value of soluble human programmed death ligand-1(sPD-L1)and vascular endothelial growth factor(VEGF)in esophageal squamous cell carcinoma(ESCC).【Methods】A total of 105 patients with postoperative pathologic diagnosis of ESCC were selected,and the other 35 healthy physical examiners were used as control group.The level of serum VEGF in patients with family history was higher than that in patients without family history.The levels of serum sPD-L1 and VEGF were determined and the differences of these between ESCC patients and healthy people were compared.The relationship between sPD-L1,VEGF and survival time was evaluated.【Results】The levels of serum sPD-L1 and VEGF had statistical significance between ESCC and disease control groups(P<0.05).The level of serum VEGF in patients with family history was higher than that in patients without family history(P<0.05).There were statistically significant differences in sPD-L1 and VEGF levels among patients with lymphonode metastasis(P<0.05).The levels of sPD-L1 and VEGF in survival time<3 years group were higher than those in survival time>3 years group(P<0.05).The ROC curve showed that the AUC of serum SPD-L1 and VEGF predicted the death of ESCC patients within 3 years was 0.820 and 0.733.The combined AUC of the three test results was 0.842 for death within 3 years.The sensitivity and specificity were 84.7%and 78.3%respectively.【Conclusion】Serum SPD-L1 and VEGF can be used as the reference for the prognosis of esophageal squamous cell carcinoma.
作者
朱曼
郭晓锋
魏昕
周福有
ZHU Man;GUO Xiaofeng;WEI Xin;ZHOU Fuyou(Laboratory,Anyang Tumor Hospital(Fourth Affiliated Hospital of Henan University of Science and Technology),Anyang,Henan 455000,China;Department of Thoracic Surgery,Anyang Tumor Hospital(Fourth Affiliated Hospital of Henan University of Science and Technology),Anyang,Henan 455000,China)
出处
《中国医学工程》
2022年第1期21-24,共4页
China Medical Engineering
作者简介
通信作者:周福有,E-mail:ayzhoufuyou@163.com,Tel:13939998799。
